Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
simultaneous tfam and tjp2 variants in a child with cirrhosis and hepatocellular carcinoma
Original title: “Simultaneous TFAM and TJP2 Variants in a Child With Cirrhosis and Hepatocellular Carcinoma.”
Study expands development of the antibody into hepatocellular carcinoma
Original title: “CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment”
alpha 1 antitrypsin deficiency alleles in non cirrhotic hepatocellular carcinoma insights from a multicenter french cohort
Original title: “Alpha-1 Antitrypsin Deficiency Alleles in Non-Cirrhotic Hepatocellular Carcinoma: Insights from a Multicenter French Cohort.”
wbc hbp dissociation unveils occult xanthogranulomatous inflammation mimicking hepatocellular carcinoma in diabetic patients
Original title: “"WBC-HBP Dissociation" Unveils Occult Xanthogranulomatous Inflammation Mimicking Hepatocellular Carcinoma in Diabetic Patients.”
impact of etiological shifts and the rising burden of non b non c hepatocellular carcinoma on surveillance and prognosis insights from a 20 year retrospective observational study
Original title: “Impact of Etiological Shifts and the Rising Burden of Non-B Non-C Hepatocellular Carcinoma on Surveillance and Prognosis: Insights From a 20-Year Retrospective Observational Study.”
atezolizumab bevacizumab in very elderly with hepatocellular carcinoma age alone is not a limiting factor except in albi grade 3
Original title: “Atezolizumab-Bevacizumab in Very Elderly With Hepatocellular Carcinoma: Age Alone Is Not a Limiting Factor Except in ALBI Grade 3.”
brd9 recognizes lactate induced h3k18 lactylation to drive oncogenic chromatin remodeling in hepatocellular carcinoma
Original title: “BRD9 recognizes lactate-induced H3K18 lactylation to drive oncogenic chromatin remodeling in hepatocellular carcinoma.”
hepatocellular carcinoma associated with hepatic sarcoidosis and budd chiari syndrome a case report and review of the literature
Original title: “Hepatocellular Carcinoma Associated with Hepatic Sarcoidosis and Budd-Chiari Syndrome: A Case Report and Review of the Literature.”
case of complete remission with durvalumab cabozantinib sequential therapy for advanced hepatocellular carcinoma
Original title: “A case of complete remission with durvalumab-cabozantinib sequential therapy for advanced hepatocellular carcinoma.”
resection combined with hyperthermic intraperitoneal chemotherapy in the treatment of spontaneously ruptured hepatocellular carcinoma a multicenter retrospective study
Original title: “Resection combined with hyperthermic intraperitoneal chemotherapy in the treatment of spontaneously ruptured hepatocellular carcinoma: a multicenter retrospective study.”
rare but fatal outcome is hepatocellular carcinoma hcc progressing to the right atrial tumor thrombus and inferior vena cava
Original title: “A rare but fatal outcome is hepatocellular carcinoma (HCC) progressing to the right atrial tumor thrombus and inferior vena cava.”